Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
We have previously developed induced-pluripotent stem cell (iPSC) lines from somatic cells of a patient with retinitis pigmentosa, which is a hereditary disease caused by gene mutation. The iPS cells were differentiated into retinal cells to reveal the mechanism of the disease in vitro, and the study proposed candidate therapeutic drugs for neuroprotection. In the current study, we treated the mouse model of retinitis pigmentosa (P23H rhodopsin knock-in mice) with one of the candidate drugs to analyze the protective effects in vivo.
|